Literature DB >> 28754417

Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1.

Yuki Ikematsu1, Yasuto Yoneshima1, Kayo Ijichi1, Kentaro Tanaka1, Taishi Harada1, Yoshinao Oda1, Yoichi Nakanishi1, Isamu Okamoto2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28754417     DOI： 10.1016/j.lungcan.2017.07.020

Source DB:  PubMed          Journal:  Lung Cancer        ISSN： 0169-5002            Impact factor:   5.705


× No keyword cloud information.
  6 in total

1.  Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung.

Authors:  Shinichiro Okauchi; Yuika Sasatani; Toshihiro Shiozawa; Hideyasu Yamada; Kunihiko Miyazaki; Norio Takayashiki; Hiroaki Satoh
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Pulmonary Pleomorphic Carcinoma Harboring EGFR Mutation Successfully Treated with Osimertinib: A Case Report.

Authors:  Yukari Kano; Nobutaka Kataoka; Yusuke Kunimatsu; Rei Tsutsumi; Izumi Sato; Mai Tanimura; Takayuki Nakano; Keiko Tanimura; Takayuki Takeda
Journal:  Medicina (Kaunas)       Date:  2022-05-26       Impact factor: 2.948

3.  Pembrolizumab - emerging treatment of pulmonary sarcomatoid carcinoma: A case report.

Authors:  Emanuela Cimpeanu; Jibran Ahmed; Wahib Zafar; Adreana DeMarinis; Svetoslav S Bardarov; Shamim Salman; Dennis Bloomfield
Journal:  World J Clin Cases       Date:  2020-01-06       Impact factor: 1.337

4.  Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.

Authors:  Kazuaki Okamura; Yuichi Fukuda; Hiroshi Soda; Daiki Ogawara; Keisuke Iwasaki; Shinichiro Fuchi; Takayuki Suyama; Masataka Yoshida; Tatsuhiko Harada; Minoru Fukuda; Hiroshi Mukae
Journal:  Thorac Cancer       Date:  2017-11-13       Impact factor: 3.500

5.  Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma.

Authors:  Hirokazu Tokuyasu; Soichiro Ishikawa; Hiromitsu Sakai; Tomoyuki Ikeuchi; Hiroshi Miura
Journal:  Respir Med Case Rep       Date:  2019-06-11

6.  Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report.

Authors:  Naoyuki Okabe; Hayato Mine; Hironori Takagi; Masayuki Watanabe; Satoshi Muto; Yuki Matsumura; Yutaka Shio; Hiroyuki Suzuki
Journal:  Thorac Cancer       Date:  2021-02-19       Impact factor: 3.500
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.